Olpresan Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil blocks the AT1 receptors for angiotensin II, preventing vasoconstriction and the release of aldosterone. This leads to relaxed blood vessels and reduced fluid retention, contributing to lower blood pressure.

The appropriate dose of Olpresan Plus is determined by a qualified prescriber based on the patient’s clinical condition, blood pressure response, and any concurrent therapies. Patients should follow the dosing instructions provided by their healthcare professional.

Olpresan Plus is generally contraindicated in pregnancy, especially during the second and third trimesters, because ARBs can harm the developing fetus. Limited data exist for breastfeeding, so use is discouraged unless the benefits clearly outweigh the risks.

To order, submit an enquiry on the Olpresan Plus product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Olpresan Plus offers a dual mechanism—ARBs for vascular relaxation and a thiazide diuretic for volume reduction—providing a convenient single‑pill option. Compared with monotherapy ARBs or diuretics, it may achieve blood‑pressure targets more efficiently in patients needing both actions.

Store Olpresan Plus at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, direct sunlight and extreme temperature fluctuations to maintain potency.

Olpresan Plus is taken orally, usually once daily, with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe hypotension, acute kidney injury, hyperkalemia, angio‑edema and significant electrolyte disturbances. Patients should be monitored for signs such as dizziness, rapid weight loss, swelling of the face or throat, and abnormal lab results.

Olpresan Plus should be avoided in patients with known hypersensitivity to olmesartan, hydrochlorothiazide or any component of the formulation, in pregnant women, and in individuals with severe renal or hepatic impairment unless specifically advised by a physician.